Introduction
Obesity affects over 1 billion people worldwide, driving risks for type 2 diabetes, cardiovascular disease, and more. GLP-1 receptor agonists like Wegovy (semaglutide) and dual GLP-1/GIP agonists like Zepbound (tirzepatide) have transformed weight management, with average losses of 15-20% in trials. Now, Roche enters the fray with CT-388, a once-weekly injectable that hit 22.5% weight loss in phase 2—outpacing Wegovy and matching Zepbound's elite performance.
This guide breaks down the trial data, mechanisms, comparisons, and implications for patients eyeing next-gen therapies.
What is CT-388 and How Does It Work?
CT-388 is a dual GLP-1/GIP receptor agonist developed by Roche after acquiring Carmot Therapeutics for $2.7 billion in 2023. Unlike single GLP-1 drugs such as semaglutide (Ozempic, Wegovy), which mimic glucagon-like peptide-1 to curb appetite and slow gastric emptying, CT-388 also activates GIP (glucose-dependent insulinotropic polypeptide).
Why dual action matters: GLP-1 reduces hunger via brain signaling and promotes insulin secretion. GIP enhances insulin response and may improve fat metabolism, potentially amplifying weight loss without plateauing early. Administered as a 24 mg weekly injection, CT-388 targets sustained effects over 48 weeks, as seen in the trial.
Mechanism Snapshot: GLP-1 slows digestion and signals fullness; GIP boosts energy expenditure and insulin sensitivity—together, superior satiety and metabolic shifts.
Phase 2 Trial Results: Breaking Down the Data
Weight Loss Achievements
In the 48-week phase 2 trial, high-dose (24 mg) CT-388 users lost an average of 22.5% body weight—no plateau observed. This exceeds Wegovy's 15-17% in similar STEP trials (e.g., STEP 1: 14.9% at 68 weeks) and aligns with Zepbound's SURMOUNT-1 results (22.5% at 72 weeks on 15 mg).
- Low dose (dose not specified): Solid losses, building dose-response evidence.
- Key edge: Continuous loss trajectory suggests potential for even greater results in longer trials.
Real-world translation: A 100 kg (220 lb) patient could shed 22.5 kg (50 lbs), transforming health markers like blood pressure and A1c.
BMI and Obesity Resolution
Remarkably, 54% of participants reduced BMI below 30 kg/m², escaping clinical obesity. Baseline BMIs were likely 35-40+, per standard trials. This outperforms Wegovy's ~30-40% non-obese responders and matches tirzepatide's profile, signaling CT-388's potency for profound metabolic reset.
Safety and Tolerability
CT-388 mirrored GLP-1 class effects: gastrointestinal issues (nausea, vomiting, diarrhea) were common but manageable, with low discontinuation rates. No new red flags emerged, akin to semaglutide's 5-7% dropout in trials. Long-term cardiac and GI safety will be phase 3 priorities, building on GLP-1 precedents like LEADER and SELECT trials showing CV benefits.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
For monitoring, apps like Shotlee can help track side effects, nutrition, and symptoms alongside therapy.
CT-388 vs. Wegovy and Zepbound: Head-to-Head Comparison
| Drug | Mechanism | Max Weight Loss (Trials) | Obesity Resolution | Dosing |
|---|---|---|---|---|
| Wegovy (semaglutide) | GLP-1 only | 15-17% (68 weeks) | ~30-40% | Weekly, up to 2.4 mg |
| Zepbound (tirzepatide) | GLP-1/GIP | 22.5% (72 weeks) | ~50% | Weekly, up to 15 mg |
| CT-388 | GLP-1/GIP | 22.5% (48 weeks) | 54% | Weekly, 24 mg |
CT-388 edges Wegovy on efficacy, leveraging GIP synergy like Zepbound. Head-to-head phase 3 trials are needed, but Roche's molecule shows promise in non-plateaus, vital for long-term adherence.
Roche's Broader Obesity Pipeline and Market Strategy
Roche, late to the $150B-by-2035 obesity market dominated by Novo Nordisk and Eli Lilly, is accelerating via acquisitions. CT-388 advances to phase 3 this quarter. Synergies include combos with petrelintide (amylin analog from Zealand Pharma, $1.65B deal), mimicking gut hormones for amplified effects—early data hints at additive losses.
Six more candidates target obesity, T2D, and hypertension by 2030, diversifying beyond injectables.
What This Means for Patients and Providers
For those on Wegovy facing plateaus or inadequate loss, CT-388 offers hope—potentially sooner via Roche's speed. Combine with lifestyle: 500 kcal deficit, resistance training preserves muscle (GLP-1s risk 20-40% lean loss). Track progress with tools like Shotlee for symptoms, diet, and adherence.
Caveats: Phase 2 is small (~200 patients?); phase 3 (thousands) confirms. Access, cost (~$1,000/month now), and insurance will shape rollout.
Conclusion
CT-388's 22.5% loss, 54% obesity resolution, and clean profile thrust Roche into GLP-1/GIP leadership. Outpacing Wegovy while rivaling Zepbound, it promises more options amid surging demand. Stay tuned for phase 3; evidence-based choices empower sustainable metabolic health.